TITLE:
An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)

CONDITION:
B-cell Lymphoma

INTERVENTION:
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months

SUMMARY:

      A study to determine the safety, tolerability, and anti-tumor effectiveness of an oral
      investigational drug in the treatment of relapsed diffuse large B-cell lymphoma.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Patient must be 18 years or older with relapsed Diffuse Large B-cell Lymphoma
             (DLBCL).

          -  Stable disease or better for at least 3 months on most recent treatment

          -  Have not received any chemotherapy, radiation therapy, major surgery, or any other
             investigational therapy for at least 4 weeks prior to entry in this study

          -  Adequate blood testing, liver, and kidney function as required by the study.

          -  Eligible subjects will allow tissue samples to be examined and stored.

        Exclusion Criteria:

          -  Patient has been treated with other investigational agents with a similar anti-tumor
             mechanism.

          -  Patient should not have failed more than 3 prior treatment regimens.
      
